X-Message-Number: 12435 From: "John de Rivaz" <> Subject: Re: Human Genome Sciences Date: Sat, 18 Sep 1999 12:16:54 +0100 (adapted from an article in the California Technology Stock newsletter. For subscription information, email Anyone interested in life extension who does not buy at least 100 shares in HGSI and keep them though thick and thin cannot be serious, in my view. But see the text below and wait until the present heat has worn off a bit though. The October dip or the dip expected in January may be a good time.) Human Genome Sciences has had a blizzard of press lately. After that big piece in the Sunday New York Times on August 29 th , CNN dedicated their September 7 th "Pinnacle" show to HGSI and CEO Bill Haseltine. It's a fascinating profile of an invalid boy who became a Harvard prof and now wants to be "the Bill Gates of biotechnology." (Hmmm.. shouldn't he have dropped out of Harvard?) There's even footage of a lady whose leg was saved from amputation by HGSI's angiogenesis drug VEGF-2. (There's a hint to young doctors here - don't study to become a surgeon.) Meanwhile, that same VEGF-2 protein got a favorable nod from the heart docs gathered in Barcelona for European Society of Cardiology meeting. The stock bounced $12 1/2 in one day in response to the apparently new-to-Wall Street thought that gene therapy might be useful in cardiac disease. Entremed and Genzyme are trying to profit from Judah Folkman's angiogenesis compounds but California Technology Stock newsletter thinks HGSI has a better approach. Wall Street Journal had an article in mid September about urotensin-II, a powerful blood-vessel constricting hormone for which HGSI found the receptor and SmithKline is now developing a drug. Dr. Bill dwelled with pleasure on the article while giving a presentation at the Bear Stearns Health Care Conference in New York. Check out SmithKline's press release on the web: it lists all the genes they've gotten from HGSI. http://www.sb.com/rd/dna_c.htm HGSI stock got a little ahead of itself by lunging up over $96 on the Barcelona news before backing off last week after the first biotech conference of the new season. (Usually, the reverse happens.) We expect the stock to retrace further as the momentum crowd is disappointed and cashes out their winnings, but buying this stock when they went public is still the equivalent of buying Coca-Cola in 1907. CTSL plan to buy more in the next dip. Find HGSI on http://www.hgsi.com -- Sincerely, John de Rivaz my homepage links to Longevity Report, Fractal Report, my singles club for people in Cornwall, music, Inventors' report, an autobio and various other projects: http://ourworld.compuserve.com/homepages/JohndeR John de Rivaz <> wrote in message news: > The company Human Genome Sciences has recently been rising sharply, and now > seems to have settled at a higher level. This is quite unusual for these bio > companies, as they usually get marked up by the market makers on some good > news and then fall back after a couple of days when investors are not buying > because they realise that it could be decades before the results of the good > news hits the company's balance sheet. > > Anyone any comment on the performance of Human Genome Sciences? Is some > interesting new life extension product or dread disease cure going to appear > available for use now? > > -- > Sincerely, John de Rivaz > my homepage links to Longevity Report, Fractal Report, my singles club for > people in Cornwall, music, Inventors' report, an autobio and various other > projects: http://ourworld.compuserve.com/homepages/JohndeR Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=12435